Publications by authors named "Mark Vanelli"
Background: Previous studies have reported that patients who are medication naive in some medication classes have a higher risk of medication discontinuation during the first 30 days of treatment and shorter median times to discontinuation than do medication-experienced patients.
Objectives: This study compared the risk of discontinuation during the first 30 days after the index fill and the median time to discontinuation for medication-naive and medication-experienced patients who were prescribed drugs for asthma, diabetes mellitus, high cholesterol, cardiovascular disease, breast cancer, glaucoma, or osteoporosis.
Methods: Deidentified outpatient pharmacy records from 4 large US retail chains were searched for patients who had obtained a prescription for one of the index medications between January 1, 2007, and January 31, 2007.
Background: In a previous study, we found that past medication use was associated with medication adherence in patients prescribed atypical antipsychotics.
Objective: The present study aimed to determine whether past medication experience was associated with adherence in patients prescribed selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors.
Methods: Deidentified computerized pharmacy records of patients from 1157 pharmacies throughout the United States were used to select patients who were dispensed extended-release venlafaxine, controlled-release paroxetine, sertraline, fluoxetine, escitalopram, and/or citalopram between October 1, 2003, and March 31, 2004.
Objective: We report on differences in atypical antipsychotic adherence after the start of outpatient treatment with atypical antipsychotics in patients receiving routine clinical care, based on whether they had been dispensed antipsychotic medication during the previous 180 days. We hypothesized that prior receipt of an antipsychotic prescription would identify patients with a reduced risk for medication discontinuation, perhaps due to greater experience with illness and/or medication experience.
Methods: De-identified computerized pharmacy records of 406,032 patients from 1157 pharmacies throughout the United States were used to select patients who were dispensed a noninjectable atypical antipsychotic between October 1, 2003, and March 31, 2004.
Background: Studies of pharmacotherapy for agitation in dementia have primarily been limited to single-drug trials and have not determined if some forms of agitated behaviors are more responsive to treatment than others.
Objective: The goal of this study was to determine if manifestations of agitation (ie, physical aggression, physically nonaggressive behavior, and verbally agitated behaviors) show different degrees of response to divalproex sodium (extended release or sprinkles) alone or in combination with second-generation antipsychotic agents.
Methods: This was a 6-week, open-label, naturalistic pilot study of patients aged >60 years recruited from a geriatric psychiatry inpatient unit, 2 nursing homes, and 4 assisted living residences.
Objective: This study evaluated time to response in the treatment of panic disorder with a selective serotonin reuptake inhibitor (SSRI) or serotonin norepinephrine reuptake inhibitor (SNRI) combined with alprazolam orally disintegrating tablets (ODT), or SSRI/SNRI alone.
Design: Subjects were randomized to eight weeks open-label treatment with alprazolam ODT (4 weeks treatment followed by 3-4 week taper) combined with an SSRI or SNRI, or treatment with SSRI/SNRI alone.
Setting: The study was conducted under naturalistic conditions at 62 primary care and 34 psychiatric practices.